Most current clinical therapies target AR-positive luminal-type tumor cells in prostate cancer; however, these treatments, either ADT or ARPIs, eventually failed because they induced lineage plasticity progression in prostate adenocarcinoma and greatly increased the number of non-luminal cells like NE-type tumor cells [41]. This evidence concerns the gene AR and Familial prostate cancer.